Wheezing-related factors for Latin American centres versus European centers (base)
| Crude OR (95% CI) | p Value | |
| Whole sample | ||
| Wheezing once or more | 1.71 (1.61 to 1.83) | <0.0001 |
| Recurrent wheezing | 1.55 (1.43 to 1.69) | <0.0001 |
| URTI first 3 months of life | 1.43 (1.34 to 1.53) | <0.0001 |
| Wheezing first 3 months of life | 1.87 (1.69 to 2.05) | <0.0001 |
| Parental history of asthma | 1.94 (1.76 to 2.14) | <0.0001 |
| Physician-diagnosed asthma | 2.05 (1.79 to 2.35) | <0.0001 |
| Eczema | 5.48 (5.05 to 5.96) | <0.0001 |
| Inhaled bronchodilator | 1.88 (1.75 to 2.01) | <0.0001 |
| Inhaled corticosteroids | 1.03 (0.95 to 1.27) | =0.48 |
| Leukotriene receptor antagonist | 0.52 (0.46 to 0.59) | <0.0001 |
| Hospital admission due to wheezing | 2.76 (2.38 to 3.19) | <0.0001 |
| ED visit due to wheezing | 2.03 (1.87 to 2.19) | <0.0001 |
| Severe wheezing episode | 2.12 (1.94 to 2.32) | <0.0001 |
| Frequent sleep disturbance due to wheezing | 1.89 (1.65 to 2.17) | <0.0001 |
| Recurrent wheezing | ||
| URTI first 3 months of life | 1.39 (1.19 to 1.62) | <0.0001 |
| Wheezing first 3 months of life | 1.59 (1.36 to 1.87) | <0.0001 |
| Parental history of asthma | 1.89 (1.46 to 2.42) | <0.0001 |
| Physician-diagnosed asthma | 1.35 (1.23 to 1.63) | =0.0014 |
| Eczema | 4.75 (3.98 to 5.66) | <0.0001 |
| Inhaled bronchodilator | 4.17 (3.41 to 5.10) | <0.0001 |
| Inhaled corticosteroids | 0.68 (0.58 to 0.79) | <0.0001 |
| Leukotriene receptor antagonist | 0.45 (0.37 to 0.56) | <0.0001 |
| Hospital admission due to wheezing | 2.43 (1.96 to 3.01) | <0.0001 |
| ED visit due to wheezing | 2.29 (1.96 to 2.68) | <0.0001 |
| Severe wheezing episode | 1.95 (1.67 to 2.28) | <0.0001 |
| Frequent sleep disturbance due to wheezing | 1.81 (1.49 to 2.19) | <0.0001 |
ED, emergency department; URTI, upper respiratory tract infection.